摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-methyl 4-(tert-butyldiphenylsilyloxy)-3-hydroxybutanoate | 124655-05-6

中文名称
——
中文别名
——
英文名称
(S)-methyl 4-(tert-butyldiphenylsilyloxy)-3-hydroxybutanoate
英文别名
methyl (3S)-4-(tert-butyldiphenylsilyloxy)-3-hydroxybutanoate;methyl (S)-4-((tert-butyldiphenylsilyl)oxy)-3-hydroxybutanoate;methyl (3S)-4-tert-butyldiphenylsilyloxy-3-hydroxybutylate;Methyl S-3-hydroxy-4-(t-butyldiphenylsilyloxy)butyrate;methyl (3S)-4-{[tert-butyl(diphenyl)silyl]oxy}-3-hydroxybutanoate;methyl (3S)-4-[tert-butyl(diphenyl)silyl]oxy-3-hydroxybutanoate
(S)-methyl 4-(tert-butyldiphenylsilyloxy)-3-hydroxybutanoate化学式
CAS
124655-05-6
化学式
C21H28O4Si
mdl
——
分子量
372.536
InChiKey
IYARNAWKJBPAJQ-KRWDZBQOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.49
  • 重原子数:
    26
  • 可旋转键数:
    9
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    55.8
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:08078ef35bd2b9401b5887ea9000815c
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4
    • 5

反应信息

点击查看最新优质反应信息

文献信息

  • Convergent total synthesis of (−)-dactylolide
    作者:Tokihiro Tanaka、Yuto Murai、Takayuki Kishi、Hiroyoshi Takamura、Isao Kadota
    DOI:10.1016/j.tetlet.2018.01.034
    日期:2018.2
    A convergent total synthesis of ()-dactylolide is described. Constructing the 2,6-disubstituted exo-methylene THP moiety was achieved by the intramolecular allylation of α-acetoxy ether. The cyclization precursor was prepared from two segments, an alcohol and carboxylic acid derivatives, by esterification followed by reductive acetylation.
    描述了(-)-癸二酰肼的会聚全合成。通过α-乙酰氧基醚的分子内烯丙基化来构建2,6-二取代的外-亚甲基THP部分。环化前体由两个部分(醇和羧酸衍生物)制备,先进行酯化反应,然后进行还原性乙酰化反应。
  • Total Synthesis of Phorboxazole A via <i>de Novo</i> Oxazole Formation: Strategy and Component Assembly
    作者:Bo Wang、T. Matthew Hansen、Ting Wang、Dimao Wu、Lynn Weyer、Lu Ying、Mary M. Engler、Melissa Sanville、Christopher Leitheiser、Mathias Christmann、Yingtao Lu、Jiehao Chen、Nicholas Zunker、Russell D. Cink、Feryan Ahmed、Chi-Sing Lee、Craig J. Forsyth
    DOI:10.1021/ja108906e
    日期:2011.2.9
    The phorboxazole natural products are among the most potent inhibitors of cancer cell division, but they are essentially unavailable from natural sources at present. Laboratory syntheses based upon tri-component fragment coupling strategies have been developed that provide phorboxazole A and analogues in a reliable manner and with unprecedented efficiency. This has been orchestrated to occur via the
    佛盒唑天然产物是癌细胞分裂最有效的抑制剂之一,但目前基本上无法从天然来源获得。已经开发了基于三组分片段偶联策略的实验室合成,以可靠的方式和前所未有的效率提供佛盒唑 A 和类似物。这是通过从两个丝氨酸衍生的酰胺依次或同时形成天然产物的两个恶唑部分来进行的,包括氧化-环化脱水。已经开发了代表碳 3-17、18-30 和 31-46 的三种预组装组件的优化制备。本文详细介绍了这三个基本构建块的设计和综合。
  • 2,4,6-substituted phenol derivatives
    申请人:Shionogi & Co., Ltd.
    公开号:US05093363A1
    公开(公告)日:1992-03-03
    A 2,4,6-substituted phenol having the formula (I): ##STR1## wherein X is S or CH.sub.2 ; R.sup.1 and R.sup.2 are the same or different from each other and each is a lower alkyl group; R.sup.3 is a group of the formula: ##STR2## in which R.sup.4 is hydrogen atom or a lower alkyl group; R.sup.5 and R.sup.6 are the same or different from each other and each is hydrogen atom, a lower alkyl group, or a phenyl group which may be substituted, or a pharmaceutically acceptable salt thereof is useful as an active agent in a pharmaceutical composition. The pharmaceutical composition comprises a therapeutically effective amount of a compound having the formula (I), as an effective ingredient, in association with a pharmaceutically acceptable substantially nontoxic carrier or excipient. The pharmaceutical composition can be useful in the treatment of lipemia of mammals. Additionally the compounds can be used as antiatherosclerotic agents and antilipenic agents.
    一种具有以下式(I)的2,4,6-取代酚:##STR1## 其中X为S或CH.sub.2;R.sup.1和R.sup.2相同或不同且均为较低的烷基基团;R.sup.3为以下式的基团:##STR2## 其中R.sup.4为氢原子或较低的烷基基团;R.sup.5和R.sup.6相同或不同且均为氢原子、较低的烷基基团或可能被取代的苯基团,或其药学上可接受的盐在制药组合物中作为有效成分是有用的。所述制药组合物包括具有式(I)的化合物的治疗有效量作为有效成分,与药学上可接受的基本无毒载体或赋形剂相关联。所述制药组合物可用于治疗哺乳动物的脂质血症。此外,这些化合物可用作抗动脉粥样硬化药物和抗脂肪药物。
  • Towards EPC-syntheses of the structural class of cochleamycins and macquarimicins. Part 3: EPC-syntheses of the β-keto lactone subunits and first attempts towards the syntheses of the pentacyclic antibiotics of this group
    作者:A. Chrobok、E. Gössinger、K. Grünberger、H. Kählig、M.J. White、F. Wuggenig
    DOI:10.1016/j.tet.2007.05.093
    日期:2007.8
    Practical EPC-syntheses of δ-substituted-β-keto δ-lactones, subunits of the cochleamycins and macquarimicins, are presented. In consequence Tietze's tandem reaction is employed to combine δ-allyl-β-keto δ-lactone with a hydrindene derivative, the second subunit of these acetogenic antibiotics. Model reactions for the final oxidative radical tandem cyclization reveal that the electrophilic radical cyclizes
    提出了实用的EPC合成的δ-取代的-β-酮δ-内酯,耳蜗霉素和麦格霉素的亚基。结果,Tietze的串联反应被用于将δ-烯丙基-β-酮δ-内酯与氢化衍生物(这些产乙酸抗生素的第二个亚基)结合。最终氧化自由基串联环化反应的模型反应表明,亲电自由基仅以exo - trig方式环化。然而,用麦格霉素的预期前体,烯丙基氢的提取阻止了氧化自由基的串联环化。
  • Total Synthesis of (−)-Bitungolide F and Determination of Its Absolute Stereochemistry
    作者:Subhash Ghosh、Soma Uday Kumar、J. Shashidhar
    DOI:10.1021/jo7023152
    日期:2008.2.1
    A highly convergent total synthesis of bitungolide F leading to the assignment of its absolute stereochemistry is described. The key steps include a Horner−Wadsworth−Emmons olefination to construct the C7−C8 bond, a Wittig reaction to introduce the conjugate E,E-olefinic moiety in the molecule, and finally a ring-closing metathesis reaction to construct the six-membered α,β-unsaturated δ-lactone of
    描述了高度收敛的bitungolide F的全合成,导致其绝对立体化学的赋值。关键步骤包括霍纳-沃兹沃思-埃蒙斯烯烃化反应以构建C7-C8键,维蒂希反应以在分子中引入共轭E,E-烯烃部分,最后是闭环易位反应以构建六元环分子的α,β-不饱和δ-内酯。使用Crimmins的方案,修改后的Evans的syn- aldol反应用于在C4和C5中心安装立体化学。使用Evans规程通过C9酮的羟基直接还原法引入C9处的立体化学。
查看更多